Business
Aclarion CEO Brent Ness to Attend LSI USA 2026
BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare
About this update from Aclarion, Inc.
[{"type":"text","content":"BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Brent Ness, Chief Executive Officer, will be attending LSI USA 2026, one of the leading conferences of global MedTech innovators, investors, and industry leaders. During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion’s continued progress advancing NOCISCAN, the company’s proprietary MR spectroscopy platform that leverages AI and biomarkers to help physicians distinguish between painful and non-painful discs in patients suffering from chronic low back pain. To schedule a 1-on-1 meeting with Mr. Ness, please email: [email protected]. LSI USA 2026Dates: March 16-20, 2026 Location: Dana Point, CAFormat: In-person 1x1 Meetings LSI USA ’26 is a premier event focused on accelerating MedTech and HealthTech innovation, bringing together investors, startups, and industry leaders. For more News from Aclarion, please visit: Latest News To find a Nociscan center, view our site map here. For more information on Nociscan, please email: [email protected] About Aclarion, Inc. Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to o...